Reports & eBooks

Drug Pipeline & Clinical Update - September 2023

October 13, 2023

Capital Rx


  • Two key new approvals: Ojjaara® for myelofibrosis and Likmez™ for trichomoniasis infections
  • Five new notable expanded indications, including for Jardiance® for patients with CKD and Ilaris® for gout flares
  • Two notable generic launches and a COVID-19 vaccine update
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review
  • Capital Rx's 3Q 2023 Pipeline Report is available

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our September 2023 Monthly Drug Update!

Key New Drug Approvals

Ojjaara® (momelotinib) tablet

Approval Date: 09/15/2023 - CLICK HERE for the press release

Indication: Myelofibrosis

Cost*: $896 per tablet

Key Considerations:

Likmez™ (metronidazole) oral suspension

Approval Date: 09/22/2023 - CLICK HERE for the press release

Indication: Trichomoniasis infections

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Jardiance® (empagliflozin 10mg) – expanded to be used to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression

Reblozyl® (luspatercept-aamt) – expanded to treat anemia without previous use of an erythropoiesis stimulating agent use in adults with very low to intermediate risk myelodysplastic syndromes who may require red blood cell transfusions

Mekinist® (trametinib) plus Tafinlar® (dabrafenib) – expanded to treat patients with unresectable or metastatic solid tumors with BRAFV600E mutation that has progressed following prior treatment and with no satisfactory alternative treatment options to include patient one to five years of age

Temodar® (temozolomide) – expanded as an adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma

Ilaris® (canakinumab) – expanded to treat adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate

Generic Launches

Retin-A Micro® (tretinoin 0.08%) gel microsphere pump

Alphagan P® (brimonidine tartrate 0.1%) ophthalmic solution

COVID-19 Updates

On September 11, 2023, the FDA authorized and approved the updated 2023-2024 monovalent XBB.1.5 variant mRNA COVID-19 vaccines by Moderna, Pfizer-BioNTech, and Novavax. CLICK HERE for the announcement.

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!